Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.72 |
| ▸ | ASAH1 | Q13510 | 2/20 | 0.72 |
| ▸ | ACER2 | Q5QJU3 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | CERT1 | Q9Y5P4 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | FAAH | O00519 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | UGCG | Q16739 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5599045 | 1.00 | ALDH1A1 (0.72) | ALDH1A1ASAH1ACER2MAPTCERT1 | |
| SCHEMBL16714723 | 1.00 | ALDH1A1 (0.72) | ALDH1A1ASAH1ACER2MAPTCERT1 | |
| SCHEMBL4183115 | 1.00 | ALDH1A1 (0.72) | ALDH1A1ASAH1ACER2MAPTCERT1 | |
| SCHEMBL4139305 | 1.00 | ALDH1A1 (0.72) | ALDH1A1ASAH1ACER2MAPTCERT1 | |
| SCHEMBL12215278 | 1.00 | ALDH1A1 (0.72) | ALDH1A1ASAH1ACER2MAPTCERT1 | |
| SCHEMBL9472620 | 1.00 | ALDH1A1 (0.72) | ALDH1A1ASAH1ACER2MAPTCERT1 | |
| SCHEMBL11857445 | 0.92 | SOAT2 (0.64) | ALDH1A1ASAH1ACER2MAPTFAAH | |
| SCHEMBL11857434 | 0.92 | SOAT2 (0.64) | ALDH1A1ASAH1ACER2MAPTFAAH | |
| SCHEMBL11396580 | 0.91 | ALDH1A1 (0.61) | ALDH1A1ASAH1ACER2MAPTCERT1 | |
| Melinamide SCHEMBL1650618 | 0.89 | EPHX2 (0.62) | ALDH1A1ASAH1ACER2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | TOUCH BIONICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | PGLS, TFPI, Q6ZSR9 | ALDH1A1 4657/4885ASAH1 3433/4885ACER2 3213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.